Skip to content

Very Early Surfactant and NCPAP for Premature Infants With RDS

Very Early Surfactant Without Mandatory Ventilation In Premature Infants Treated With Early Continuous Positive Airway Pressure-A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00563641
Acronym
CNRNCPAP
Enrollment
278
Registered
2007-11-26
Start date
2004-01-31
Completion date
2006-12-31
Last updated
2007-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lung Disease, Pneumothorax/Pulmonary Intersticial Emphysema, Respiratory Distress Syndrome

Keywords

NCPAP, Very early surfactant

Brief summary

The present study will test the use of very early nasal continuous airway pressure(NCPAP)with and without surfactant in premature infants with clinical evidence or respiratory distress syndrome. We hypothesize that premature infants exposed to very early NCPAP and surfactant will require less mechanical ventilation compared to those premature infants exposed to NCPAP alone.

Detailed description

Premature infants who are not intubated during the first 15 minutes of life and who develop clinical evidence of respiratory distress or need for oxygen requirement between 15 and 60 minutes of life, will be placed on bubble NCPAP of 6 cm H2O. Randomization envelops will them be opened and patients will be assigned to continuation on NCPAP alone (Control Group) or to NCPAP plus very early surfactant therapy (Treatment Group). Patients assigned to the treatment group will be transiently intubated for surfactant administration, extubated, and placed back on NCPAP of 6 cm H2O. Both groups will then be followed over time to determine which infants meet treatment failure criteria defined as: Treatment failure was defined a priori by either failure of adequate oxygenation or ventilation as follows: 1 FiO2 greater than 0.75 for more than 30 minutes to maintain SpO2 within the pre-established target ranges, 2 persistent or recurrent desaturation below 80% that did not respond to suctioning of the airways and PPV, 3 PCO2\>65 mmHg and pH\<7.22 on an arterial or capillary blood gas analysis, in association with increased work of breathing. Infants in the Treatment Group who cannot be extubated after their initial dose of surfactant because of clinical instability will be analyzed as treatment failures. Premature infants that meet treatment failure criteria on either arm will be intubated and placed on mechanical ventilation and given surfactant rescue doses according to the criteria of the participating institutions. Premature infants with respiratory distress syndrome who do not meet treatment failure criteria in both groups will remain on NCPAP until their respiratory failure improves.

Interventions

OTHERVery early surfactant and bubble NCPAP

For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O

Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria.

Sponsors

Pontificia Universidad Javeriana
CollaboratorOTHER
Vanderbilt University School of Medicine
CollaboratorOTHER
Abbott
CollaboratorINDUSTRY
Fisher and Paykel Healthcare
CollaboratorINDUSTRY
Colombian Neonatal Research Network
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
27 Weeks to 31 Weeks
Healthy volunteers
No

Inclusion criteria

* Gestational age of 27 to 31 6/7 weeks, * Postnatal age between 15 and 60 minutes, * Supplemental oxygen requirement or evidence of increased work of breathing (tachypnea, intercostal retractions, nasal flaring, or grunting), and * Prenatal consent.

Exclusion criteria

* Apgar score less than 2 at 5 minutes, * Intubation prior to randomization, * Prenatal diagnosis of major congenital anomalies, * Prolonged rupture of membranes of greater than 3 weeks duration, and * Infants who were likely to be transferred to another center soon after birth were not enrolled in the study.

Design outcomes

Primary

MeasureTime frame
Need for mechanical ventilationDeath or discharge from the NICU

Secondary

MeasureTime frame
Neonatal mortalityDuring hospitalization in the NICU
Air leak syndromedeath or discharge from the NICU
Oxygen dependency at 36 weeks post menstrual ageDeath or discharge from the NICU

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026